分流手术与仑卡奈单抗治疗特发性正常压力脑积水合并阿尔茨海默病两例报告
本文报告两例特发性正常压力脑积水(iNPH)合并阿尔茨海默病(AD)患者,分别接受不同顺序的脑室腹腔(VP)或腰腹腔(LP)分流手术与仑卡奈单抗治疗。未观察到出血并发症,但作者指出关于安全性的结论应谨慎解读。
要点
- iNPH常与AD共存,分流手术是iNPH的常用治疗方式。
- 仑卡奈单抗可能引起出血性影像学异常,围手术期出血风险需关注。
- 两例患者不同顺序治疗均未出现出血并发症,但安全性结论需谨慎。
核心结论
- 两例iNPH合并AD患者接受不同顺序的分流手术与仑卡奈单抗治疗,未观察到出血并发症,但安全性结论需谨慎解读。
研究设计与样本
- 病例报告,共两例特发性正常压力脑积水合并阿尔茨海默病患者。
主要发现
- 两例患者采用不同顺序的分流手术(脑室腹腔或腰腹腔)与仑卡奈单抗治疗,均未发生出血并发症。
临床怎么用
- 对于iNPH合并AD需行分流手术且考虑仑卡奈单抗治疗的患者,应关注围手术期出血风险并个体化安排治疗顺序。
局限性
- 仅基于两例病例报告,样本量极小,无法就安全性得出确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic normal pressure hydrocephalus (iNPH) is a condition in the elderly commonly treated with ventriculoperitoneal (VP) or lumboperitoneal (LP) shunt surgery. iNPH frequently coexists with Alzheimer's disease (AD), for which anti-amyloid-β antibodies such as lecanemab have recently become available. Because lecanemab may cause hemorrhagic imaging abnormalities, the timing of shunt surgery in relation to antibody therapy raises concern regarding perioperative bleeding risk. Here, we report two patients with iNPH and AD treated with different sequences of shunt surgery and lecanemab. No hemorrhagic complications were observed, although conclusions regarding safety should be interpreted cautiously.
引用
- Miyazaki K, Morita H, Ishii K, et al. Shunt surgery and lecanemab therapy in patients with idiopathic normal pressure hydrocephalus and alzheimer's disease: a report of two cases. Acta Neurochir (Wien). 2026. PMID: 41729309. doi:10.1007/s00701-026-06804-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。